From research to the real world: buprenorphine in the decade of the Clinical Trials Network.
Ling
Walter
W
Pacific Region Node, University of California, Los Angeles, USA.
Jacobs
Petra
P
Hillhouse
Maureen
M
Hasson
Albert
A
Thomas
Christie
C
Freese
Thomas
T
Sparenborg
Steven
S
McCarty
Dennis
D
Weiss
Roger
R
Saxon
Andrew
A
Cohen
Allan
A
Straus
Michele
M
Brigham
Gregory
G
Liu
David
D
McLaughlin
Paul
P
Tai
Betty
B
D000286:Administration, Sublingual; D002047:Buprenorphine / Q000009:adverse effects / Q000627:therapeutic use*; D000069479:Buprenorphine, Naloxone Drug Combination; D002986:Clinical Trials as Topic; D003153:Community Health Services / Q000379:methods; D004338:Drug Combinations; D006801:Humans; D009270:Naloxone / Q000009:adverse effects / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009294:Narcotics / Q000009:adverse effects / Q000627:therapeutic use; D054577:National Institute on Drug Abuse (U.S.); D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D017450:Receptors, Opioid, mu / Q000819:agonists; D014481:United States
D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009294:Narcotics; D017450:Receptors, Opioid, mu; D009270:Naloxone; D002047:Buprenorphine